TGTX TG Therapeutics, Inc.
TG Therapeutics, Inc. (TGTX) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.5% since its last earnings release on August 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About TG Therapeutics, Inc.
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
Sector
Healthcare
Industry
Drug Manufacturers/Other